Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 393 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Patient Guide in Testicular Cancer Now Available Also in Italian November 25, 2025 ESMO Welcomes Draft Report on Europe’s Beating Cancer Plan (BCP) Which... April 1, 2026 Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress April 30, 2020 Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult... December 13, 2024 Load more HOT NEWS Potential for Larger Gene Panels to Increase the Number of Molecularly... Breast Cancer Patient Takes Silly Pictures During Each Radiation Treatment to... ΚΑΡΚΙΝΟΣ ΩΟΘΗΚΩΝ Why I Choose to Live With Gratitude During Metastatic Breast Cancer
